Under the terms of the agreement, BioWa will provide GlaxoSmithKline (GSK) with non-exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access fees, and may receive milestone payments and royalties from resulting products which are developed by GSK. Additional terms were not disclosed.
According to BioWa, Potelligent technology improves potency and efficacy of antibody therapeutics, by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of action for antibody therapeutics.
Masamichi Koike, BioWa’s president and CEO, said: “GSK is recognized as a key player in the field of antibody drug discovery. We believe this represents an important opportunity to promote the development of more effective targeted treatments for debilitating diseases where enhanced ADCC might offer a significant therapeutic benefit.”